fda compounding restrictions bpc 157 FDA's own advisory committee voted 8-6 Thursday. BPC-157, on the list now, for ulcerative colitis. staff argued against it, laid out the data gaps, the whole case. Panel overruled them You may have heard buzz
You may have heard buzz about 14 peptides potentially returning to legal compounding. Here's what we know: HHS Secretary RFK Jr. stated his intention to move these peptides from FDA Category 2 BREAKING: The FDA just reversed theIR 2023 peptide ban. 12 peptides were just pulled from the Category 2 restricted list: 1. BPC 157 2. Thymosin beta 4 fragment (TB 500) 3. Epitalon 4. GHK Cu (injectable) Big changes could be coming for peptides. On July 2324, the FDA will hold public hearings on peptides like BPC 157, MOTS c, KPV, Semax, and Epitalon. If they're supported, access through compounding pharmacies BPC 157 just got voted in favor to be added to the 503A Bulk Drug Substances list, meaning a huge step towards being able to be prescribed and compounded in the US. Thank
Pay in 4 interest-free payments of $5.26 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11